about
Pharmacology and Clinical Drug Candidates in Redox MedicineReactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical IndicationsHDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegenerationDecreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulationHDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivoAltered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease.Voltage-Gated Proton Channels as Novel Drug Targets: From NADPH Oxidase Regulation to Sperm BiologyDiscovery of GSK2795039, a Novel Small Molecule NADPH Oxidase 2 Inhibitor.What have we learned from gene expression profiles in Huntington's disease?NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?Functional properties of alpha7 nicotinic acetylcholine receptors co-expressed with RIC-3 in a stable recombinant CHO-K1 cell line.Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease.Diminished activity-dependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments.Molecular cloning and characterization of a novel human variant of RIC-3, a putative chaperone of nicotinic acetylcholine receptors.A subset of N-substituted phenothiazines inhibits NADPH oxidases.Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicity.
P50
Q26785525-49C8A8C1-B052-4FE1-A434-2EEB67532425Q27024762-665F3CA6-F698-423F-A1E6-06EF03D69F7DQ27316520-3C012BAE-3564-4207-BA50-D0666B4D7D98Q28479035-5C75161C-9102-467D-9E23-754ACD5CC6F5Q28535389-94D2DD4A-DA18-4457-842A-5DC562A5525BQ30474580-88042EEF-ADAF-4604-8E62-9F0AFF28BFCAQ35977268-CA244119-2443-4B0F-A156-49E0B50C3EBEQ35984159-31C3488E-05C4-4AA0-9ED8-055BC09E2E03Q37912519-0EE6AC80-A80F-4E86-A476-005514FECA35Q38623284-B90B4268-72CA-4411-9B9E-30DE4D588D1DQ39983549-3083114C-2C66-4E40-9B1C-4AF8CB2BAE12Q42097305-3EA67686-AEA7-4224-8EE0-0C68F2FA28F2Q42719599-49EC5D01-F3F1-4017-AA8F-3FB54DE867D9Q43534744-BE81CB36-D79E-47C4-ADB0-BF035B856958Q46437662-2756D7A5-C089-4F5F-B244-971DB2807F0CQ46723608-F633B131-6CE8-4590-B558-3350E30247A5Q53295099-B7F4CD43-3B35-4419-B136-DC3260C02D14
P50
name
Tamara Seredenina
@ast
Tamara Seredenina
@en
Tamara Seredenina
@es
Tamara Seredenina
@nl
type
label
Tamara Seredenina
@ast
Tamara Seredenina
@en
Tamara Seredenina
@es
Tamara Seredenina
@nl
prefLabel
Tamara Seredenina
@ast
Tamara Seredenina
@en
Tamara Seredenina
@es
Tamara Seredenina
@nl